Shares of Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) dropped 2.5% on Friday . The company traded as low as $22.16 and last traded at $22.17, with a volume of 102,815 shares. The stock had previously closed at $22.73.

A number of research firms recently weighed in on ENTA. Zacks Investment Research cut shares of Enanta Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, April 12th. Vetr cut shares of Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $35.45 price objective on the stock. in a report on Monday, April 25th. Finally, JMP Securities cut shares of Enanta Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, April 28th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $28.58.

The stock’s 50-day moving average price is $22.95 and its 200 day moving average price is $26.45. The company has a market capitalization of $420.09 million and a PE ratio of 13.03.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, May 9th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by $0.19. The firm had revenue of $13 million for the quarter, compared to analyst estimates of $16.80 million. The company’s revenue was down 77.4% compared to the same quarter last year. During the same quarter last year, the firm posted $1.49 EPS. Equities research analysts forecast that Enanta Pharmaceuticals Inc. will post $1.00 earnings per share for the current fiscal year.

Several large investors recently made changes to their positions in the company. Cornerstone Capital Management Holdings LLC. increased its stake in shares of Enanta Pharmaceuticals by 114.7% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 32,851 shares of the company’s stock valued at $1,085,000 after buying an additional 17,551 shares during the last quarter. First Trust Advisors LP acquired a new stake in Enanta Pharmaceuticals during the fourth quarter worth $1,374,000. EQIS Capital Management increased its stake in Enanta Pharmaceuticals by 382.0% in the fourth quarter. EQIS Capital Management now owns 44,836 shares of the company’s stock worth $1,480,000 after buying an additional 35,534 shares in the last quarter. GSA Capital Partners LLP increased its stake in Enanta Pharmaceuticals by 44.3% in the fourth quarter. GSA Capital Partners LLP now owns 80,322 shares of the company’s stock worth $2,652,000 after buying an additional 24,670 shares in the last quarter. Finally, New York State Common Retirement Fund increased its stake in Enanta Pharmaceuticals by 8.0% in the fourth quarter. New York State Common Retirement Fund now owns 133,569 shares of the company’s stock worth $4,410,000 after buying an additional 9,871 shares in the last quarter.

Enanta Pharmaceuticals Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.